Phase 1 Results of Zilebesiran Published in the New England Journal of Medicine

Phase 1 Results of Zilebesiran Published in the New England Journal of Medicine

Results from the Phase 1 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, were published in the New England Journal of Medicine (NEJM).

Read the manuscript